Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 3
1982 1
1983 5
1984 2
1985 3
1986 2
1987 3
1988 1
1989 2
1990 2
1991 4
1992 6
1993 10
1994 9
1995 8
1996 8
1997 8
1998 13
1999 17
2000 13
2001 24
2002 29
2003 44
2004 61
2005 70
2006 90
2007 104
2008 81
2009 112
2010 133
2011 137
2012 161
2013 189
2014 214
2015 239
2016 227
2017 241
2018 299
2019 331
2020 409
2021 404
2022 332
Text availability
Article attribute
Article type
Publication date

Search Results

3,653 results
Results by year
Filters applied: . Clear all
Page 1
Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.
Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, Li H, Bath PM, Dong Q, Xu A, Jing J, Lin J, Niu S, Wang Y, Zhao X, Li Z, Jiang Y, Li W, Liu L, Xu J, Chang L, Wang L, Zhuang X, Zhao J, Feng Y, Man H, Li G, Wang B; CHANCE-2 Investigators. Wang Y, et al. Among authors: xu a. N Engl J Med. 2021 Dec 30;385(27):2520-2530. doi: 10.1056/NEJMoa2111749. Epub 2021 Oct 28. N Engl J Med. 2021. PMID: 34708996 Clinical Trial.
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Ren Z, et al. Among authors: xu a. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143971 Clinical Trial.
Mapping the genetic landscape of DNA double-strand break repair.
Hussmann JA, Ling J, Ravisankar P, Yan J, Cirincione A, Xu A, Simpson D, Yang D, Bothmer A, Cotta-Ramusino C, Weissman JS, Adamson B. Hussmann JA, et al. Among authors: xu a. Cell. 2021 Oct 28;184(22):5653-5669.e25. doi: 10.1016/j.cell.2021.10.002. Epub 2021 Oct 20. Cell. 2021. PMID: 34672952 Free article.
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F. Qin S, et al. Among authors: xu a. J Clin Oncol. 2021 Sep 20;39(27):3002-3011. doi: 10.1200/JCO.21.00163. Epub 2021 Jun 29. J Clin Oncol. 2021. PMID: 34185551 Clinical Trial.
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics.
Leppek K, Byeon GW, Kladwang W, Wayment-Steele HK, Kerr CH, Xu AF, Kim DS, Topkar VV, Choe C, Rothschild D, Tiu GC, Wellington-Oguri R, Fujii K, Sharma E, Watkins AM, Nicol JJ, Romano J, Tunguz B, Participants E, Barna M, Das R. Leppek K, et al. Among authors: xu af. bioRxiv. 2021 Mar 30:2021.03.29.437587. doi: 10.1101/2021.03.29.437587. Preprint. bioRxiv. 2021. PMID: 33821271 Free PMC article.
Reply.
Ma D, Liu X, Yang Y, Xu A. Ma D, et al. Among authors: xu a. J Hypertens. 2021 Aug 1;39(8):1728-1729. doi: 10.1097/HJH.0000000000002883. J Hypertens. 2021. PMID: 34188010 No abstract available.
Efficient C•G-to-G•C base editors developed using CRISPRi screens, target-library analysis, and machine learning.
Koblan LW, Arbab M, Shen MW, Hussmann JA, Anzalone AV, Doman JL, Newby GA, Yang D, Mok B, Replogle JM, Xu A, Sisley TA, Weissman JS, Adamson B, Liu DR. Koblan LW, et al. Among authors: xu a. Nat Biotechnol. 2021 Nov;39(11):1414-1425. doi: 10.1038/s41587-021-00938-z. Epub 2021 Jun 28. Nat Biotechnol. 2021. PMID: 34183861 Free PMC article.
3,653 results